B2Prime and cTrader Expand Trading Opportunities with a New Partnership
B2Prime, a leading global multi-asset and multi-market Prime of Prime liquidity provider, and Spotware, a premier and innovative trading platform provider, have announced a strategic partnership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610848632/en/
B2Prime, a Prime of Prime multi-asset liquidity provider, and cTrader, Spotware's flagship trading platform, have established a strategic partnership to expand trading opportunities. (Graphic: Business Wire)
The cTrader platform by Spotware is renowned for its advanced features that cater to professional traders:
Clear and stunning UI → Visually appealing and comprehensive user interface with a possibility for deep customisation.
Multi-asset trading without latency → A diverse range of supported asset classes alongside lightning-fast order entry and execution.
Depth of market (DOM) → Level II pricing empowers traders to evaluate market sentiment and anticipate potential price movements with higher accuracy.
Top availability → cTrader offers cross-platform accessibility with its Desktop, Mac, Web and Mobile (iOS and Android) apps.
Advanced risk management → cTrader users are equipped with sophisticated protection tools to trade with confidence.
Algo trading solutions → Out-of-the-box ecosystem for algo trading, with cBots, indicators and plugins.
Social trading platform → cTrader Copy is an integrated platform where strategy providers and investors meet.
Nicholas Chrysochos, Executive Director of B2Prime, remarks:
"Numerous hedge funds, money managers, professional traders, algorithmic traders, systematic traders, and high-net-worth individuals have shown a keen interest in accessing our extensive liquidity pool. In response to this growing demand, we have chosen cTrader as the platform through which these clients can access our bespoke liquidity products across a wide range of jurisdictions. We are licensed by CySEC, allowing us to serve the entire EU market, and we also hold licenses in Mauritius and Seychelles. This strategic growth is part of our commitment to helping our clients excel in competitive global markets."
Currently, B2Prime has several outstanding platforms, namely OneZero, PrimeXM, now cTrader, and FIX API connectivity.
Ilia Iarovitcyn, CEO of Spotware Systems, comments:
“We are excited to continuously develop our liquidity provision network, expand the asset offering and enhance the reliability of our trading environment. Partnering with B2Prime contributes to delivering competitive pricing and an exceptional trading experience to our end users. With our cutting-edge technology and B2Prime’s strategic growth, we are confident in driving innovation and success for our clients globally.”
The collaboration between B2Prime and Spotware extends B2Prime’s range of services and significantly enhances cTrader’s liquidity offering, making it even more competitive. With a portfolio of over 200 instruments across six asset classes—FOREX, Crypto CFDs, Spot Indices, Precious Metals, Commodities, and NDFs—B2Prime offers one of the most comprehensive liquidity solutions on the market.
The company guarantees access to the deepest liquidity pools sourced from the most reputable providers, ensuring competitive spreads and swift execution. Additionally, B2Prime provides multi-currency prime margin accounts and an institutional tiered-margin approach.
Spotware is a global technology provider, successfully delivering cutting-edge fintech solutions and infrastructure for over 14 years. The company has cultivated a sophisticated network of 240+ brokers and prop firms. With a user base exceeding 4 million traders, cTrader, Spotware’s flagship platform, stands out for its unparalleled innovativeness and user-friendly UI, setting new standards across the industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610848632/en/
Contact information
B2Prime
info@b2prime.com
+357 25 582 192
Spotware
sales@spotware.com
+357 25 344 902
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom